Wagner Paul A.

Average Profitability
50.28%
Insider Buys Quantity
12
Insider Buys Sum
$281,067.71
Insider Sells Quantity
1
Insider Sells Sum
$4.35M

Insider Activity of Wagner Paul A.

According to the SEC Form 4 filings, Wagner Paul A., being in a position of

  1. See Remarks at Forte Biosciences, Inc.,
    оver the last 12 months, has bought 118865 shares for $75,040, and sold 0 shares,
    over all time since 2020-06-25, has bought 225865 shares for $281,068, and sold 1000000 shares for $4.35M.

The largest purchase of all time was on 2020-06-25 and amounted to 7000 shares of Forte Biosciences, Inc. for $101,356.

The largest sale of all time was on 2021-09-07 and amounted to 1000000 shares of Forte Biosciences, Inc. for $4.35M.

Biography of Wagner Paul A.

No biography is available at this moment.

2023-12-18PurchaseForte Biosciences, Inc.
FBRX
See Remarks
10,000
0.0286%
$0.75$7,525-16.2%
2023-12-14PurchaseForte Biosciences, Inc.
FBRX
See Remarks
10,000
0.0287%
$0.72$7,200-13.06%
2023-12-13PurchaseForte Biosciences, Inc.
FBRX
See Remarks
10,520
0.0284%
$0.70$7,351-14.11%
2023-12-12PurchaseForte Biosciences, Inc.
FBRX
See Remarks
4,776
0.013%
$0.65$3,088-8.09%
2023-12-11PurchaseForte Biosciences, Inc.
FBRX
See Remarks
25,000
0.0719%
$0.65$16,188-1.25%
2023-12-08PurchaseForte Biosciences, Inc.
FBRX
See Remarks
15,000
0.0406%
$0.62$9,300-0.85%
2023-12-07PurchaseForte Biosciences, Inc.
FBRX
See Remarks
36,203
0.0971%
$0.58$21,168+4.69%
2023-11-22PurchaseForte Biosciences, Inc.
FBRX
See Remarks
400
0.0011%
$0.43$172+38.42%
2023-11-20PurchaseForte Biosciences, Inc.
FBRX
See Remarks
6,966
0.0175%
$0.44$3,048+21.82%
2022-12-16PurchaseForte Biosciences, Inc.
FBRX
See Remarks
44,024
0.2759%
$1.07$47,000+2.04%
2022-12-15PurchaseForte Biosciences, Inc.
FBRX
See Remarks
55,976
0.3253%
$1.03$57,672-1.96%
2021-09-07SaleForte Biosciences, Inc.
FBRX
See Remarks
1M
7.2851%
$4.35$4.35M-65.57%
2020-06-25PurchaseForte Biosciences, Inc.
FBRX
See Remarks
7,000
0.1998%
$14.48$101,356+150.76%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.